Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 36
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
País de afiliação
Intervalo de ano de publicação
3.
Lupus ; 25(7): 735-40, 2016 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-26876692

RESUMO

OBJECTIVES: Benefits of hydroxychloroquine (HCQ) use on physician reported outcomes are well documented in systemic lupus erythematosus (SLE). We assess for the first time the association and predictive value of blood HCQ levels towards health-related quality of life (HRQOL) in SLE. METHODS: Data from the PLUS study (a randomized, double-blind, placebo-controlled, multicentre study) were utilized. Blood HCQ levels were quantified by high-performance liquid chromatography along with HRQOL assessments (Medical Outcomes Study-SF-36) at baseline (V1) and month 7 (V2). RESULTS: 166 SLE patients' data were analysed. Mean (SD) age and disease duration were 44.4 (10.7) and 9.3 (6.8) years. Eighty-seven per cent were women. Mean (SD, median, IQR) HCQ concentrations in the blood at V1 were 660 (314, 615, 424) ng/ml and increased to 1020 (632, 906, 781) ng/ml at V2 (mean difference 366 units, 95% confidence interval -472 to -260, p < 0.001). No significant correlations between HCQ concentrations with HRQOL domains at V1 or V2 were noted. There were no differences in HRQOL stratified by HCQ concentrations. HCQ concentrations at V1 or changes in HCQ concentration (V2-V1) were not predictive of HRQOL at V2 or changes in HRQOL (V2-V1). CONCLUSIONS: No association of HCQ concentrations with current or longitudinal HRQOL were found in SLE.


Assuntos
Antirreumáticos/sangue , Hidroxicloroquina/sangue , Lúpus Eritematoso Sistêmico/sangue , Qualidade de Vida , Adulto , Método Duplo-Cego , Feminino , França , Humanos , Modelos Lineares , Masculino , Pessoa de Meia-Idade
4.
Rev Med Interne ; 42(6): 438-441, 2021 Jun.
Artigo em Francês | MEDLINE | ID: mdl-33531232

RESUMO

INTRODUCTION: Hyperkalemia is common in medicine and requires rapid management. Besides the easily evoked causes such as renal failure, adrenal insufficiency, cell lysis or iatrogenic causes, false or pseudo-hyperkalemia should not be forgotten. OBSERVATIONS: Three patients (1 man, 2 women, aged 78, 84, 88) were managed for thrombocytosis (between 1306 and 2404 G/L) and non-symptomatic hyperkalemia (between 6.1 and 7.7mmol/L) are reported. Kalemia on blood collected in heparin tube was normal (4.4-4.6mmol/L). Therefore, no specific treatment for this pseudohyperkalemia was required. CONCLUSION: The combination of thrombocytosis and non-symptomatic hyperkalemia should suggest the diagnosis of pseudohyperkalemia and should prompt for a control of kalemia on blood collected in heparin tube. The recognition of this diagnosis is important in order to avoid unnecessary and potentially deleterious treatment of hyperkalemia.


Assuntos
Hiperpotassemia , Trombocitose , Feminino , Heparina , Humanos , Hiperpotassemia/diagnóstico , Hiperpotassemia/terapia , Masculino , Potássio , Trombocitose/diagnóstico , Trombocitose/terapia
5.
Rev Med Interne ; 41(8): 562-566, 2020 Aug.
Artigo em Francês | MEDLINE | ID: mdl-32674890

RESUMO

INTRODUCTION: Prostatic abscesses are usually diagnosed in the setting of bacterial prostatitis. Rarely, they reveal or complicate granulomatous prostatitis. CASE REPORT: A 55-year-old man was admitted for acute urinary retention. Urine culture was sterile, with leukocyturia > 106/ml. After failure of antibiotic therapy with cefotaxime, CT scan revealed a necrotic prostatic collection and a nodular non-necrotic tissular lesion in the left upper lung lobe. Trans-rectal drainage of the prostatic lesion and lung biopsies revealed granuloma with multinucleated giant cells (without mycobacteria). The diagnosis of granulomatosis with polyangiitis was confirmed by high level of anti-proteinase 3 antibodies. Treatment with steroids and rituximab resulted in apyrexia, regression of the inflammatory syndrome and clinical manifestations. CONCLUSION: The diagnosis of granulomatosis with polyangiitis should be considered in the presence of a non-infectious granulomatous prostatitis with systemic involvement.


Assuntos
Abscesso/complicações , Granulomatose com Poliangiite/complicações , Prostatite/complicações , Abscesso/diagnóstico , Abscesso/tratamento farmacológico , Glucocorticoides/uso terapêutico , Granulomatose com Poliangiite/diagnóstico , Granulomatose com Poliangiite/tratamento farmacológico , Humanos , Masculino , Pessoa de Meia-Idade , Prostatite/diagnóstico , Prostatite/tratamento farmacológico , Rituximab/uso terapêutico , Retenção Urinária/diagnóstico , Retenção Urinária/tratamento farmacológico , Retenção Urinária/etiologia
6.
Rev Med Interne ; 41(10): 704-707, 2020 Oct.
Artigo em Francês | MEDLINE | ID: mdl-32861533

RESUMO

INTRODUCTION: Although tuberculous meningitis is an uncommon presentation of tuberculosis, it still remains one of the deadliest forms of this disease. In this context, the occurrence of a cerebral infarct is an aggravating factor. OBSERVATION: A 48-year-old Asian man presented himself in the emergency room for dysarthria and dysphagia of progressive onset. Cerebral CT showed a recent ischemic defect of the right internal capsule. Lumbar puncture showed meningitis with low sugar levels. Pulmonary micronodules on the thoracic CT suggested tuberculosis, which was confirmed by a broncho-alveolar lavage. Anti-tuberculosis treatment and early corticosteroid resulted in an improvement of the patient's state. CONCLUSION: Cerebral infarctions in patients with tuberculous meningitis are events that cannot be underestimated in terms of frequency or severity. Their poor prognosis is partly the result of insufficiently defined management, which combines anti-tuberculosis treatment and early corticosteroid therapy.


Assuntos
Infarto Cerebral/etiologia , Tuberculose Meníngea/complicações , Antituberculosos/uso terapêutico , Infarto Cerebral/diagnóstico , Infarto Cerebral/tratamento farmacológico , Glucocorticoides/uso terapêutico , Humanos , Masculino , Pessoa de Meia-Idade , Tuberculose Meníngea/diagnóstico , Tuberculose Meníngea/tratamento farmacológico
7.
Ann Dermatol Venereol ; 136 Suppl 7: S417-25, 2009 Dec.
Artigo em Francês | MEDLINE | ID: mdl-20110057

RESUMO

Among diagnostic progress over the last three years in internal medicine, Antisynthetase Syndrome is now more easily recognised with the diffusion of laboratory tests for research of antibodies against tRNA synthetases (Anti JO1, anti PL7, Anti PL12). In two third of cases, these antibodies are found despite absence of antinuclear antibodies. Hence, we have to search them specifically in patients with polyarthritis associated with myositis, cutaneous manifestations (Raynaud phenomenom and "mechanic'hands") and interstitial lung disease. Discovery of asymptomatic mutation in the L ferritin coding sequence help us to better understand the "unexplained" hyperferritinemia. Initially described by japonese gastroenterologists, auto immune pancreatitis in fact a part of a systemic sclerosing disease with a biochemical hallmark: in crease of a subclass of immunoglobulins G (IgG4). A new pediatric disease due to a deficiency of the interleukin1 receptor antagonist (multifocal aseptic osteitis, periostitis, stomatitis, disseminated pustulosis) help us to better understand unexplained auto inflammatory diseases. The therapeutic progress is primarily due to an explosion of biological therapies, particularly four of them very useful for internists (in an off label use) : Interleukin 1 inhibitors (anakinra, Canakinumab) to treat some auto inflammatory diseases (cryopirin associated periodic syndromes and deficency of interleukin 1 receptor antagonist), monoclonal antibody against interleukin 5 (mepolizumab) to treat some hypereosinophilic syndromes and Churg and Strauss angiitis, interleukin 6 inhibitiors to treat multifocal Castleman's disease and adult Still disease, a monoclonal antibody against vascular endothelial growth factor (Bevacizumab) to treat hereditary hemorrhagic telangiectasia.


Assuntos
Doenças Autoimunes/diagnóstico , Doenças Autoimunes/imunologia , Medicina Interna/tendências , Pustulose Exantematosa Aguda Generalizada/diagnóstico , Pustulose Exantematosa Aguda Generalizada/imunologia , Aminoacil-tRNA Sintetases/imunologia , Anticorpos Monoclonais/uso terapêutico , Artrite/diagnóstico , Artrite/imunologia , Autoanticorpos/imunologia , Doenças Autoimunes/tratamento farmacológico , Doenças Autoimunes/genética , Biomarcadores/metabolismo , Quimioterapia Combinada , Ferritinas/genética , Humanos , Proteína Antagonista do Receptor de Interleucina 1/uso terapêutico , Interleucina-6/antagonistas & inibidores , Sobrecarga de Ferro/diagnóstico , Sobrecarga de Ferro/genética , Doenças Pulmonares Intersticiais/diagnóstico , Doenças Pulmonares Intersticiais/imunologia , Mutação , Miosite/diagnóstico , Miosite/imunologia , Osteíte/diagnóstico , Osteíte/imunologia , Pancreatite/diagnóstico , Pancreatite/imunologia , Periostite/diagnóstico , Periostite/imunologia , Doença de Raynaud/diagnóstico , Doença de Raynaud/imunologia , Estomatite/diagnóstico , Estomatite/imunologia , Síndrome , Resultado do Tratamento
8.
Clin Rheumatol ; 38(5): 1243-1249, 2019 May.
Artigo em Inglês | MEDLINE | ID: mdl-30617596

RESUMO

INTRODUCTION: Some studies suggest that there is an increased risk of malignancies in giant cell arteritis (GCA). We aimed to describe the clinical characteristics and outcomes of GCA patients with concomitant malignancy and compare them to a GCA control group. METHOD: Patients with a diagnosis of GCA and malignancy and with a maximal delay of 12 months between both diagnoses were retrospectively included in this study and compared to a control group of age-matched (3:1) patients from a multicenter cohort of GCA patients. RESULTS: Forty-nine observations were collected (median age 76 years). Malignancies comprised 33 (67%) solid neoplasms and 16 (33%) clonal hematologic disorders. No over-representation of a particular type of malignancy was observed. Diagnosis of GCA and malignancy was synchronous in 7 (14%) patients, while malignancy succeeded GCA in 29 (59%) patients. Malignancy was fortuitously diagnosed based on abnormalities observed in laboratory tests in 26 patients, based on imaging in 14 patients, and based on symptoms or clinical examination in the nine remaining patients. Two patients had a concomitant relapse of both conditions. When compared to the control group, patients with concomitant GCA and malignancy were more frequently male (p < 0.001), with an altered general state (p < 0.001), and polymyalgia rheumatica (p < 0.01). CONCLUSIONS: This study does not indicate an over-representation of any particular type of malignancy in GCA patients. Initial follow-up dictated by vasculitis may have led to an early identification of malignancy. Nevertheless, GCA male patients with an altered general state and polymyalgia rheumatica might more frequently show concomitant malignancies.


Assuntos
Arterite de Células Gigantes/complicações , Neoplasias/complicações , Polimialgia Reumática/complicações , Idoso , Feminino , França , Humanos , Masculino , Estudos Retrospectivos , Medição de Risco
10.
Rev Med Interne ; 28(11): 770-4, 2007 Nov.
Artigo em Francês | MEDLINE | ID: mdl-17629593

RESUMO

INTRODUCTION: Erdheim-Chester disease is a rare non-Langerhans form of histiocytosis. We report the use of combined fluorodeoxyglucose positron emission tomography and computed tomography (18F-FDG PET-CT) in this disease. EXEGESIS: Three men, aged from 55 to 74 years with confirmed Erdheim-Chester disease were included. 18F-FDG PET-CT allowed to detect visceral and vascular involvement of the disease which were overlooked with CT-scan or magnetic resonance imaging: left common carotid and ilio-femoral artery in one patient, coronary, femoral and tibia in the second, aortic, common carotid, femoral and mandibula in the remaining patient. Also, sequential 18F-FDG PET-CT was useful to appreciate treatment efficiency (decrease hyperfixation) and decide treatment modification (interferon alpha). CONCLUSION: 18F-FDG PET-CT combined imaging allows to assess the extent of involvement in Erdheim-Chester disease. 18F-FDG PET-CT may be also a useful tool in the management of Erdheim-Chester disease.


Assuntos
Doença de Erdheim-Chester/diagnóstico por imagem , Idoso , Aorta Torácica/diagnóstico por imagem , Fluordesoxiglucose F18 , Humanos , Masculino , Tomografia por Emissão de Pósitrons , Compostos Radiofarmacêuticos , Tomografia Computadorizada por Raios X
13.
Leukemia ; 19(5): 792-8, 2005 May.
Artigo em Inglês | MEDLINE | ID: mdl-15772698

RESUMO

Idiopathic hypereosinophilic syndrome (HES) characterized by unexplained and persistent hypereosinophilia is heterogeneous and comprises several entities: a myeloproliferative form where myeloid lineages are involved with the interstitial chromosome 4q12 deletion leading to fusion between FIP1L1 and PDGFRA genes, the latter acquiring increased tyrosine kinase activity. And a lymphocytic variant, where hypereosinophilia is secondary to a primitive T lymphoid disorder demonstrated by the presence of a circulating T-cell clone. We performed molecular characterization of HES in 35 patients with normal karyotype by conventional cytogenetic analysis. TCRgamma gene rearrangements suggesting T clonality were seen in 11 (31%) patients, and FIP1L1-PDGFRA by RT-PCR in six (17%) of 35 patients, who showed no evidence of T-cell clonality. An elevated serum tryptase level was observed in FIP1L1-PDGFRA-positive patients responding to imatinib, whereas serum IL-5 levels were not elevated in T-cell associated hypereosinophilia. Sequencing FIP1L1-PDGFRA revealed scattered breakpoints in FIP1L1-exons (10-13), whereas breakpoints were restricted to exon 12 of PDGFRA. In the 29 patients without FIP1L1-PDGFRA, no activating mutation of PDGFRA/PDGFRB was detected; however; one patient responded to imatinib. FISH analysis of the 4q12 deletion was concordant with FIP1L1-PDGFRA RT-PCR data. Further investigation of the nature of FIP1L1-PDGFRA affected cells will improve the classification of HES.


Assuntos
Deleção Cromossômica , Análise Citogenética , Síndrome Hipereosinofílica/diagnóstico , Síndrome Hipereosinofílica/genética , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Sequência de Bases , Benzamidas , Cromossomos Humanos Par 12/genética , Cromossomos Humanos Par 4/genética , Éxons , Feminino , França , Humanos , Síndrome Hipereosinofílica/tratamento farmacológico , Mesilato de Imatinib , Hibridização in Situ Fluorescente/métodos , Interleucina-5/sangue , Masculino , Pessoa de Meia-Idade , Dados de Sequência Molecular , Piperazinas/administração & dosagem , Piperazinas/uso terapêutico , Pirimidinas/administração & dosagem , Pirimidinas/uso terapêutico , Análise de Sequência de DNA , Serina Endopeptidases/sangue , Triptases
14.
Rev Med Interne ; 27(7): 569-72, 2006 Jul.
Artigo em Francês | MEDLINE | ID: mdl-16510215

RESUMO

INTRODUCTION: The nucleopathy calcifying of the inter vertebral disk is mostly asymptomatic. CASE RECORD: We report a cave miming a spondylodiscit. DISCUSSION: Although idiopatic in most case, it is necessary to look for a calcifying metabolic disease. The treatment base on the immobilization of the spine and non steroidal anti inflammatory medications.


Assuntos
Calcinose/complicações , Disco Intervertebral/patologia , Dor Lombar/etiologia , Vértebras Lombares/patologia , Doenças da Coluna Vertebral/complicações , Adulto , Diagnóstico Diferencial , Discite/diagnóstico , Feminino , Humanos
15.
Rev Med Interne ; 37(6): 387-93, 2016 Jun.
Artigo em Francês | MEDLINE | ID: mdl-26415922

RESUMO

INTRODUCTION: Retroperitoneal fibrosis (RPF) is a rare disorder characterized by the sheathing of retroperitoneal structures by fibro-inflammatory process. It can be either isolated or associated with an underlying disease or condition. In the absence of consistent and consensual approach, the objective of this study was to assess the relevance of diagnostic tests performed during the diagnostic work-up of RPF. METHODS: Seventy-seven patients were included in this retrospective multicenter study. The diagnosis of RPF was defined by the presence of a thickened circumferential homogeneous tissue unsheathing the infrarenal aorta, excluding peri-aneurysmal fibrosis and a clear evidence of a cancer. RESULTS: In 62 cases (80.5%), the RPF was considered as being primary or "idiopathic". Surgical (n=31) or CT-guided (n=9) biopsies of the RPF were performed in half of the patients showing some fibrotic or non-specific inflammatory lesions in 98% of cases. A bone marrow biopsy was performed in 23 patients leading to diagnosis of low grade B cell non-Hodgkin lymphoma in a single patient who also had a monoclonal gammopathy IgM. The systematic search for autoantibodies or serum tumor markers was of no diagnostic value. CONCLUSIONS: Although the diagnostic procedure was heterogeneous, no cause or associated disease was found in the majority of cases of FRP in this series. In the absence of any clinical or paraclinical evidence suggesting an underlying disease or any atypical features at presentation, a number of non-invasive tests (autoantibodies, tumor markers, bone scintigraphy) and also more invasive diagnostic tests (bone marrow and RPF biopsies) seem of little relevance.


Assuntos
Técnicas e Procedimentos Diagnósticos , Fibrose Retroperitoneal/diagnóstico , Adulto , Idoso , Idoso de 80 Anos ou mais , Diagnóstico Diferencial , Técnicas e Procedimentos Diagnósticos/normas , Feminino , Humanos , Imunoglobulina G/metabolismo , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Fibrose Retroperitoneal/epidemiologia , Estudos Retrospectivos , Adulto Jovem
16.
Rev Med Interne ; 36(5): 346-51, 2015 May.
Artigo em Francês | MEDLINE | ID: mdl-25544147

RESUMO

Amyloidosis is a rare group of diseases related to extracellular deposition of proteins in an insoluble beta-pleated sheet structure presenting a characteristic apple-green birefringence under polarized light after Congo red staining. Thirty types of proteins are known to cause amyloidosis. The accurate identification of the amyloid protein is of paramount importance since it is a key step for the clinical management and personalized treatment. Amyloid typing is usually based on immunohistochemistry and immunofluorescence on tissular sections. This approach has several limits leading to a subtyping failure rate of 15 to 58% of cases. To overcome these difficulties, proteomic methods have been developed to characterize directly the amyloid protein. The most advanced technique carried out on fixed and paraffin-embedded tissue consists of laser microdissection followed by mass spectrometry. The type of amyloidosis can be determined in more than 95% of cases. However, the experience for this technique is very limited apart from the Mayo Clinic (Rochester, United States). In France, a very close proteomic assay has been implemented in the department of pathology of Foch Hospital with similar results. The introduction of proteomics in clinical practice represents a major improvement for typing amyloidosis. In this article, we discuss the benefits and limits of the different techniques used for amyloid classification and we briefly report our proteomic results.


Assuntos
Amiloidose/classificação , Amiloidose/diagnóstico , Proteômica/métodos , Sequência de Aminoácidos , Amiloide/química , Amiloide/metabolismo , Amiloidose/metabolismo , Apolipoproteína A-I/química , Apolipoproteína A-I/metabolismo , Humanos , Imuno-Histoquímica/métodos , Dados de Sequência Molecular
17.
Arthritis Rheumatol ; 67(8): 2176-84, 2015 May.
Artigo em Inglês | MEDLINE | ID: mdl-25989906

RESUMO

OBJECTIVE: Blood concentrations of hydroxychloroquine (HCQ) vary widely among patients with systemic lupus erythematosus (SLE). A pharmacokinetic/pharmacodynamic relationship has been found in different situations, and a very low blood concentration of HCQ is a simple marker of nonadherence to treatment. Therefore, interest in blood HCQ concentration measurement has increased, but little is known about factors that influence blood HCQ concentration variability. This study was undertaken to analyze determinants of blood HCQ concentrations. METHODS: We conducted a retrospective analysis of patient data, including data from the Plaquenil Lupus Systemic (PLUS) study, to determine the association of epidemiologic, clinical, and biologic factors with blood HCQ concentrations. Data for nonadherent patients (blood HCQ concentration <200 ng/ml) were excluded. RESULTS: To examine homogeneous pharmacologic data, we restricted the analyses of the PLUS data to the 509 SLE patients receiving 400 mg/day. We found no association of ethnicity or smoking with blood HCQ concentrations and no pharmacokinetic drug-drug interaction with antacids or with inhibitors or inducers of cytochrome P450 enzymes. On multivariate analysis, high body mass index (P = 0.008), no treatment with corticosteroids (P = 0.04), increased time between the last tablet intake and measurement of blood HCQ concentrations (P = 0.017), low platelet count (P < 0.001), low neutrophil count (P < 0.001), and high estimated creatinine clearance (P < 0.001) were associated with low blood HCQ concentrations. In 22 SLE patients with chronic renal insufficiency (median serum creatinine clearance 52 ml/minute [range 23-58 ml/minute]) who received 400 mg/day HCQ, the median blood HCQ concentration was significantly higher than that in the 509 patients from the PLUS study (1,338 ng/ml [range 504-2,229 ng/ml] versus 917 ng/ml [range 208-3316 ng/ml]) (P < 0.001). CONCLUSION: We provide a comprehensive analysis of determinants of blood HCQ concentrations. Because this measurement is increasingly being used, these data might be useful for clinicians.


Assuntos
Corticosteroides/uso terapêutico , Antirreumáticos/farmacocinética , Hidroxicloroquina/farmacocinética , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Adulto , Antirreumáticos/sangue , Antirreumáticos/uso terapêutico , Índice de Massa Corporal , Creatinina/sangue , Feminino , Humanos , Hidroxicloroquina/sangue , Hidroxicloroquina/uso terapêutico , Contagem de Leucócitos , Lúpus Eritematoso Sistêmico/sangue , Lúpus Eritematoso Sistêmico/complicações , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Neutrófilos/citologia , Obesidade/complicações , Insuficiência Renal Crônica/complicações , Estudos Retrospectivos , Trombocitopenia , Fatores de Tempo , Adulto Jovem
18.
J Neurol Sci ; 94(1-3): 79-100, 1989 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-2559165

RESUMO

Glial cytoplasmic inclusions (GCIs) were demonstrated by silver staining, immunocytochemistry and by electron microscopy in the central nervous system (CNS) of 11 patients with various combinations of striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome. Although their configuration in light microscope can sometimes resemble neurofibrillary tangles, their cellular localisation, measurements, ultrastructure, immunocytochemical characteristics and regional distribution all differ from these Alzheimer type changes. The majority of GCIs were localized in the white matter and appeared to be accompanied by an increase in the number of interfascicular oligodendroglial cells and pallor or loss of myelin staining. Our histological, ultrastructural and immunocytochemical findings all indicate that the cells which contain GCIs are oligodendrocytes and the inclusions themselves are composed of tubular structures. The presence of the until now unknown GCIs in all the 11 CNS, but not in age- and sex-matched control brains, indicates that GCI is a cellular change characteristic of multiple system atrophy and the three syndromes are various manifestations of the same disease.


Assuntos
Doenças do Sistema Nervoso Autônomo/patologia , Corpo Estriado/patologia , Corpos de Inclusão/patologia , Neuroglia/patologia , Atrofias Olivopontocerebelares/patologia , Síndrome de Shy-Drager/patologia , Degenerações Espinocerebelares/patologia , Substância Negra/patologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade
19.
Blood Coagul Fibrinolysis ; 13(5): 461-3, 2002 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-12138375

RESUMO

Double heterozygosity for factor V R506Q and prothrombin G20210A mutations was identified in a 24-year-old man with beta-thalassemia major. The patient experienced a first thrombotic event at the age of 19 years and three recurrent thromboses in a short time interval, the third occurring while the patient was receiving long-term anticoagulant treatment. This case suggests that patients with major thalassemia and congenital thrombophilic mutations need intensive and long-lasting anticoagulant treatment. Thus, even if thrombotic events could be explained by a hypercoagulable state observed in patients with major thalassemia, after a first thrombotic event has occurred these patients should be screened for acquired and congenital thrombophilia.


Assuntos
Resistência à Proteína C Ativada/complicações , Fator V/genética , Protrombina/genética , Embolia Pulmonar/etiologia , Trombofilia/genética , Tromboflebite/etiologia , Talassemia beta/complicações , Regiões 3' não Traduzidas/genética , Resistência à Proteína C Ativada/genética , Adulto , Anticoagulantes/uso terapêutico , Aspirina/uso terapêutico , Predisposição Genética para Doença , Heparina de Baixo Peso Molecular/uso terapêutico , Heterozigoto , Humanos , Masculino , Veia Poplítea , Embolia Pulmonar/tratamento farmacológico , Recidiva , Veia Safena , Esplenectomia , Tromboflebite/tratamento farmacológico , Talassemia beta/genética
20.
Rev Med Interne ; 24(11): 748-52, 2003 Nov.
Artigo em Francês | MEDLINE | ID: mdl-14604753

RESUMO

INTRODUCTION: Castleman's disease (CD) is a polyclonal lymphoplasmacytic and vascular proliferation prominent in lymphoid tissues, associated to Human Herpesvirus 8 (HHV-8) in Human Immunodeficiency Virus (HIV)-infected patients. The presence of autoimmune stigmates is frequent. EXEGESIS: We report two cases of neutropenia secondary to IgG neutrophil autoantibodies, indeterminate specificity, occurring in two HIV-infected patients with CD HHV-8+, treated by vinblastine since several years. The neutropenia was associated to other biologic stigmates of autoimmunity and the evolution has been complicated by several infections. Granulocyte-colony stimulating factor (G-CSF) and polyvalent immunoglobulin permitted a transient and low increase of neutrophila in one case. CONCLUSION: Auto-immune neutropenia in CD is rare and difficult to treat in our cases. This evolution is independent of relapse of CD. The immunoglobulin and G-CSF may be transitory effective.


Assuntos
Hiperplasia do Linfonodo Gigante/complicações , Infecções por HIV/complicações , Infecções por Herpesviridae/complicações , Herpesvirus Humano 8 , Neutropenia/imunologia , Antineoplásicos Fitogênicos/uso terapêutico , Autoanticorpos/sangue , Hiperplasia do Linfonodo Gigante/tratamento farmacológico , Infecções por HIV/tratamento farmacológico , Infecções por Herpesviridae/tratamento farmacológico , Humanos , Imunoglobulina G/sangue , Masculino , Pessoa de Meia-Idade , Neutropenia/tratamento farmacológico , Resultado do Tratamento , Vimblastina/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA